Therapeutic Proteins and Oral Vaccines Market Size, Share & Trends Analysis Report By Drug Class, By Distribution Channel, By Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, Other Applications), By Region, And By Segment Forecasts, 2024-2031

Report Id: 1037 Pages: 180 Last Updated: 30 May 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Global Therapeutic Proteins and Oral Vaccines Market Segmentation

Global Therapeutic Proteins and Oral Vaccines Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Drug Class

  • Therapeutic Proteins
  • Growth Factors
  • Fusion Proteins
  • Monoclonal Antibodies
  • Hormones
  • Coagulation Factors
  • Other Therapeutic Proteins
  • Oral Vaccines
  • Live Attenuated Vaccine
  • Inactivated Vaccine
  • Recombinant Vaccine
  • Other Oral Vaccines

therapeutic protein

Global Therapeutic Proteins and Oral Vaccines Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Therapeutic Proteins and Oral Vaccines Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Applications

  • Oncology
  • Hematology
  • Immunology
  • Endocrinology
  • Infectious Disease
  • Cardiovascular Disease
  • Other Applications

Global Therapeutic Proteins and Oral Vaccines Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Therapeutic Proteins and Oral Vaccines Market Revenue (US$ Million) By Country,

  • U.S.
  • Canada

Europe Therapeutic Proteins and Oral Vaccines Market Revenue (US$ Million) By Country,

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Therapeutic Proteins and Oral Vaccines Market Revenue (US$ Million) By Country, 

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Therapeutic Proteins and Oral Vaccines Market Revenue (US$ Million) By Country, 

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Revenue (US$ Million) By Country, 

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Therapeutic Proteins and Oral Vaccines Market Snapshot

Chapter 4. Global Therapeutic Proteins and Oral Vaccines Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Drug Class, Estimates & Trend Analysis

5.1. By Drug Class, & Market Share, 2019 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Drug Class:

5.2.1. Therapeutic Proteins

5.2.1.1.  Growth Factors

5.2.1.2.  Fusion Proteins

5.2.1.3.  Monoclonal Antibodies

5.2.1.4.  Hormones

5.2.1.5.  Coagulation Factors

5.2.1.6.  Other Therapeutic Proteins

5.2.2. Oral Vaccines

5.2.2.1.  Live Attenuated Vaccine

5.2.2.2.  Inactivated Vaccine

5.2.2.3.  Recombinant Vaccine

5.2.2.4.  Other Oral Vaccines

Chapter 6. Market Segmentation 1: By Distribution Channels Estimates & Trend Analysis

6.1. By Distribution Channels & Market Share, 2019 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution Channels:

6.2.1. Hospital Pharmacies

6.2.2. Retail Pharmacies

6.2.3. Online Pharmacies

Chapter 7. Market Segmentation 1: By Applications Estimates & Trend Analysis

7.1. By Applications & Market Share, 2019 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Applications:

7.2.1. Oncology

7.2.2. Hematology

7.2.3. Immunology

7.2.4. Endocrinology

7.2.5. Infectious Disease

7.2.6. Cardiovascular Disease

7.2.7. Other Applications

Chapter 8. Therapeutic Proteins and Oral Vaccines Market Segmentation 3: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) estimates and forecasts By Drug Class, 2024-2031

8.1.2. North America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) estimates and forecasts By Distribution Channels, 2024-2031

8.1.3. North America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) estimates and forecasts By Applications, 2024-2031

8.1.4. North America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) estimates and forecasts by country, 2024-2031

8.2. Europe

8.2.1. Europe Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Drug Class, 2024-2031

8.2.2. Europe Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Distribution Channels, 2024-2031

8.2.3. Europe Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Applications, 2024-2031

8.2.4. Europe Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) by country, 2024-2031

8.3. Asia Pacific

8.3.1. Asia Pacific Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Drug Class, 2024-2031

8.3.2. Asia Pacific Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Distribution Channels, 2024-2031

8.3.3. Asia Pacific Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Applications, 2024-2031

8.3.4. Asia Pacific Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) by country, 2024-2031

8.4. Latin America

8.4.1. Latin America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Drug Class, (US$ Million) 2024-2031

8.4.2. Latin America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Distribution Channels, (US$ Million) 2024-2031

8.4.3. Latin America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Applications, (US$ Million) 2024-2031

8.4.4. Latin America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) by country, (US$ Million) 2024-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Drug Class, (US$ Million) 2024-2031

8.5.2. Middle East & Africa Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Distribution Channels, (US$ Million) 2024-2031

8.5.3. Middle East & Africa Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Applications, (US$ Million) 2024-2031

8.5.4. Middle East & Africa Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) by country, (US$ Million) 2024-2031

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Abbott Laboratories

9.2.2. Amgen, Inc.

9.2.3. Biogen, Inc.

9.2.4. Eily, Lilly, and Company

9.2.5. F. Hoffmann-La Roche

9.2.6. Johnson and Johnson

9.2.7. Merck & Co.

9.2.8. Novo Nordisk

9.2.9. Pfizer, Inc.

9.2.10. Sanofi S.A.

9.2.11. Serum Institute of India Pvt. Ltd.

9.2.12. Emergent Biosolutions Inc.

9.2.13. TransAlgae

9.2.14. MigVax Ltd

9.2.15. Lumen Bioscience, Inc.

9.2.16. Neurelis, Inc.

9.2.17. Other Prominent Player

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
2319
Security Code field cannot be blank!

Frequently Asked Questions

The Therapeutic Proteins and Oral Vaccines Market Size is valued at USD 239.91 Million in 2023 and is predicted to reach USD 436.26 Million by the yea

The Therapeutic Proteins and Oral Vaccines Market is expected to grow at an 8.1 % CAGR during the forecast period for 2024-2031.

Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying